Related Experiment Video
Updated: Aug 27, 2025
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Coronavirus 2019 disease: Are corticosteroids the key treatment? A retrospective case-control study in Brazil
Salete S Rios1, Ana C R Chen1, Juliana R Chen1
1School of Medicine - University of Brasília - Campus Darcy Ribeiro, Asa Norte Brasília-DF, CEP 70910700, Brazil.
Background:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the putative cause of coronavirus disease 2019 (COVID-19), a serious disease that has severely impacted the world. Although vaccines have been developed, it will take time to inoculate the global population. Current guidelines have focused on the treatment of severe cases in hospital settings; however, a void has been created regarding appropriate measures for those in the initial stage of COVID-19 and those experiencing moderate disease severity progressing to desaturation. We assessed clinical outcomes in patients with COVID-19 with pneumonia at initial presentation treated with corticosteroids.
Methods:
Data of 177 consecutive high-risk patients with COVID-19, monitored by telemedicine, were collected and analyzed. Of those, 68 patients were in the initial inflammatory phase of the disease without desaturation and received corticosteroids. The outcomes were evaluated after a follow up of 14 days. Four patients were immediately referred to the hospital because they had explicit desaturation at presentation.
Results:
After 14 days, all patients in the inflammatory phase at presentation who were treated with corticosteroids before desaturation were alive and without complications. However, of the four patients with desaturation, one died at the hospital.
Conclusion:
In this study, the use of corticosteroids during the initial pulmonary phase of COVID-19 before desaturation, in addition to daily monitoring of patients, prevented disease progression, decreased the risk of complications and incidence of hospitalization and death. However, additional studies with larger number of patients are needed to confirm these findings.
Insights
Corticosteroid treatment for early-stage COVID-19 pneumonia before desaturation, combined with telemedicine monitoring, improved patient outcomes. This approach reduced disease progression, complications, hospitalizations, and deaths in high-risk individuals.
Area of Science:
- Infectious Diseases
- Pulmonology
- Clinical Medicine
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a global health crisis.
- Existing treatment guidelines primarily address severe cases, leaving a gap for early and moderate COVID-19.
- The study investigates corticosteroid use in initial COVID-19 pneumonia before oxygen desaturation.
Purpose of the Study:
- To assess the clinical outcomes of COVID-19 patients with pneumonia treated with corticosteroids during the initial inflammatory phase.
- To determine if early corticosteroid intervention can prevent disease progression in high-risk patients.
Main Methods:
- Retrospective analysis of 177 high-risk COVID-19 patients monitored via telemedicine.
- 68 patients received corticosteroids during the initial inflammatory phase without desaturation.
- Outcomes were evaluated after a 14-day follow-up period.
Main Results:
- All patients treated with corticosteroids before desaturation survived without complications after 14 days.
- Four patients with initial desaturation were hospitalized, and one died.
- Early corticosteroid intervention appeared to prevent severe outcomes.
Conclusions:
- Corticosteroid use in the early pulmonary phase of COVID-19, prior to desaturation, can prevent disease progression.
- This treatment, alongside telemedicine monitoring, reduces complications, hospitalizations, and mortality.
- Larger studies are needed to confirm these promising findings.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.